open access

Vol 85, No 5 (2014)
ARTICLES
Get Citation

Urinary tract infection in pregnant population, which empirical antimicrobial agent should be specified in each of the three trimesters?

Bekir Serdar Unlu, Yunus Yidiz, Metin Kaba, Cuma Kara, Selcuk Erkilinc, Ibrahim Keles, Halil Kara
DOI: 10.17772/gp/1744
·
Ginekol Pol 2014;85(5).

open access

Vol 85, No 5 (2014)
ARTICLES

Abstract

Objective: We aimed to investigate the bacterial profile and the adequacy of antimicrobial treatment in pregnant women with urinary tract infection. Material and Methods: This retrospective observational study was conducted with 753 pregnant women who needed hospitalization because of UTI in each of the three trimesters. Midstream urine culture and antimicrobial susceptibility tests were evaluated. Results: E.Coli was the most frequently isolated bacterial agent (82.2%), followed by Klebsiella spp. (11.2%). In each of the three trimesters, E.Coli remained the most frequently isolated bacterium (86%, 82.2%, 79.5%, respectively), followed by Klebsiella spp. (9%, 11.6%, 12.2%, respectively). Enterococcus spp. were isolated as a third microbial agent, with 43 patients (5.7%) in the three trimesters. The bacteria were found to be highly sensitive to fosfomycin, with 98-99% sensitivity for E.Coli and 88-89% for Klebsiella spp. and for Enterococcus spp. 93-100% nitrofurantoin sensitivity for each of the three trimesters. Conclusions: We demonstrated that E.Coli and Klebsiella spp. are the most common bacterial agents isolated from urine culture of pregnant women with UTI in each of the three trimesters. We consider fosfomycin to be the most adequate first-line treatment regimen due to high sensitivity to the drug, ease of use and safety for use in pregnancy.

Abstract

Objective: We aimed to investigate the bacterial profile and the adequacy of antimicrobial treatment in pregnant women with urinary tract infection. Material and Methods: This retrospective observational study was conducted with 753 pregnant women who needed hospitalization because of UTI in each of the three trimesters. Midstream urine culture and antimicrobial susceptibility tests were evaluated. Results: E.Coli was the most frequently isolated bacterial agent (82.2%), followed by Klebsiella spp. (11.2%). In each of the three trimesters, E.Coli remained the most frequently isolated bacterium (86%, 82.2%, 79.5%, respectively), followed by Klebsiella spp. (9%, 11.6%, 12.2%, respectively). Enterococcus spp. were isolated as a third microbial agent, with 43 patients (5.7%) in the three trimesters. The bacteria were found to be highly sensitive to fosfomycin, with 98-99% sensitivity for E.Coli and 88-89% for Klebsiella spp. and for Enterococcus spp. 93-100% nitrofurantoin sensitivity for each of the three trimesters. Conclusions: We demonstrated that E.Coli and Klebsiella spp. are the most common bacterial agents isolated from urine culture of pregnant women with UTI in each of the three trimesters. We consider fosfomycin to be the most adequate first-line treatment regimen due to high sensitivity to the drug, ease of use and safety for use in pregnancy.
Get Citation

Keywords

empirical antimicrobial agent, pregnancy, Urinary tract infection

About this article
Title

Urinary tract infection in pregnant population, which empirical antimicrobial agent should be specified in each of the three trimesters?

Journal

Ginekologia Polska

Issue

Vol 85, No 5 (2014)

DOI

10.17772/gp/1744

Bibliographic record

Ginekol Pol 2014;85(5).

Keywords

empirical antimicrobial agent
pregnancy
Urinary tract infection

Authors

Bekir Serdar Unlu
Yunus Yidiz
Metin Kaba
Cuma Kara
Selcuk Erkilinc
Ibrahim Keles
Halil Kara

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl